JOURNAL OF AD-DIN AKIJ MEDICAL COLLEGE

Vol. 3 | No. 2 | July 2024
JAAMC 2024; 3(1): 08−11

EDITORIAL

Beyond Bones: The Expanding Role of Vitamin D in Metabolic and Cardiovascular Health

For decades, Vitamin D has been viewed primarily as the “bone vitamin” essential for calcium-phosphate homeostasis and skeletal health. While its role in preventing rickets and osteomalacia is undisputed, a growing body of evidence suggests that Vitamin D has far-reaching effects extending into metabolic and cardiovascular systems. This evolving understanding necessitates a paradigm shift: Vitamin D is not merely a nutrient for bones but a pleiotropic hormone influencing multiple organ systems (1).

Vitamin D as a Hormone: Biological Basis for Expanded Roles

Vitamin D functions more like a steroid hormone than a conventional vitamin. Upon activation, it binds to the Vitamin D Receptor (VDR), which is expressed in more than 30 tissues, including pancreatic β-cells, skeletal muscle, vascular smooth muscle, and cardiomyocytes (2). Through genomic and non-genomic actions, Vitamin D regulates over 200 genes involved in inflammation, cell growth, and metabolic regulation. This widespread distribution of VDRs provides a biological rationale for the diverse systemic effects observed in clinical and epidemiological studies (3).

Vitamin D and Metabolic Health: Diabetes and Insulin Resistance

One of the most consistent areas of research links Vitamin D with glucose metabolism. Experimental studies have shown that Vitamin D directly influences insulin secretion by binding to VDRs in pancreatic β-cells. It also improves insulin sensitivity in peripheral tissues by enhancing expression of insulin receptors and modulating intracellular calcium (4).

Epidemiological studies reveal that Vitamin D deficiency is associated with higher prevalence of type 2 diabetes and metabolic syndrome (5). While some randomized controlled trials demonstrate modest improvements in insulin resistance after Vitamin D supplementation, others fail to show significant benefit (6). These mixed results may be explained by variations in baseline deficiency status, genetic differences in VDR polymorphisms, and heterogeneity in dosage and duration of supplementation.

Obesity and Adipose Tissue Function

Obesity is both a cause and consequence of Vitamin D deficiency. Adipose tissue sequesters Vitamin D, reducing its bioavailability. Conversely, deficiency exacerbates obesity-related metabolic dysfunction by increasing systemic inflammation and impairing lipid metabolism (7). Emerging research suggests that Vitamin D may regulate adipokines such as leptin and adiponectin, thereby influencing energy balance and fat distribution (8).

Vitamin D and Cardiovascular Health:Hypertension and Vascular Function

The renin–angiotensin–aldosterone system (RAAS) plays a pivotal role in hypertension and cardiovascular disease. Vitamin D has been shown to suppress renin expression, thus attenuating RAAS overactivity (9). Observational studies consistently demonstrate an inverse relationship between

serum Vitamin D levels and blood pressure (10). However, supplementation trials yield conflicting outcomes—some report modest blood pressure reduction, while others show no effect (11).

Atherosclerosis and Coronary Artery Disease

Vitamin D deficiency is strongly associated with endothelial dysfunction, vascular stiffness, and increased inflammatory burden—all key contributors to atherosclerosis (12). Experimental studies indicate that Vitamin D modulates macrophage activity, reduces foam cell formation, and inhibits vascular smooth muscle proliferation (13). These anti-atherosclerotic effects provide a mechanistic link to observational findings that low Vitamin D status correlates with higher incidence of coronary artery disease, myocardial infarction, and stroke (14).

Heart Failure and Arrhythmias

The presence of VDRs in cardiomyocytes suggests a direct role for Vitamin D in cardiac remodeling and contractility (15). Deficiency is linked with left ventricular hypertrophy and increased risk of heart failure (16). Furthermore, disturbances in calcium homeostasis caused by inadequate Vitamin D may predispose to arrhythmias (17). While supplementation has not yet emerged as a definitive therapy for heart failure, ongoing trials are exploring its potential in adjunctive management (18).

Controversies and Challenges

Despite promising associations, translating Vitamin D research into clinical recommendations remains fraught with challenges. Several large randomized controlled trials, such as the VITAL study, reported neutral results regarding cardiovascular outcomes (19), raising questions about causality. Critics argue that the benefits of Vitamin D may be confined to individuals with frank deficiency, while supplementation in those with sufficient baseline levels offers little advantage (20).

Another complexity lies in determining the optimal threshold for sufficiency. While most guidelines define deficiency as serum 25(OH)D levels below 20 ng/mL, some experts advocate for higher cut-offs (≥30 ng/mL) for optimal cardiometabolic protection (21). The debate underscores the need for individualized approaches considering genetics, lifestyle, and comorbidities.

Public Health and Clinical Implications

Vitamin D deficiency is highly prevalent worldwide, particularly in South Asia, the Middle East, and parts of Africa, where sun exposure is limited by lifestyle and cultural practices (22). In Bangladesh, recent surveys indicate deficiency rates exceeding 60% in certain populations. This widespread deficiency presents both a challenge and an opportunity.

From a clinical standpoint, screening for Vitamin D deficiency in patients with diabetes, obesity, or cardiovascular disease may help identify those at risk. From a public health perspective, fortification of staple foods and community-level supplementation programs could serve as cost-effective strategies to mitigate the burden of cardiometabolic diseases (23).

Future Directions

To fully elucidate the role of Vitamin D in metabolic and cardiovascular health, future research must address several gaps:

- Precision medicine approaches: Genetic studies on VDR polymorphisms may help identify subgroups that derive the greatest benefit from supplementation (24).

- Long-term interventional trials: Large, well-designed trials with adequate dosing and longer follow-up are needed to establish causality (25).
- Integration with digital health: Wearables and AI-based prediction models could track sun exposure, dietary intake, and serum levels, personalizing Vitamin D recommendations (26).
- Combination therapies: Studying Vitamin D supplementation alongside other interventions—such as statins, antihypertensives, or antidiabetic agents—may reveal synergistic effects (27).

Conclusion

The journey of Vitamin D research has evolved from rickets prevention to exploring its potential in reducing the global burden of chronic diseases. While definitive evidence remains elusive, the expanding role of Vitamin D in metabolic and cardiovascular health is undeniable. For clinicians, the message is clear: ensure sufficiency, particularly in high-risk groups, while awaiting further evidence to refine therapeutic strategies. For researchers, the challenge is to untangle causality from association and move from observational promise to clinical impact.

Vitamin D, once considered merely the guardian of bone health, is now emerging as a silent modulator of the heart, vessels, and metabolism. Its story is still being written—but the chapters ahead may redefine preventive medicine in the 21st century.

References

1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007; 357(3):266–281.

2. Bouillon R, Marcocci C, Carmeliet G, et al. Skeletal and extraskeletal actions of vitamin D: current evidence and outstanding questions. Endocr Rev. 2019; 40(4):1109–1151.

3. Bikle DD. Vitamin D: Production, metabolism, and mechanisms of action. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext. 2017.

4. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2007; 92(6):2017–2029.

5. Pittas AG, Dawson-Hughes B, Sheehan P, et al. Vitamin D supplementation and prevention of type 2 diabetes. N Engl J Med. 2019; 381:520–530.

6. Mousa A, Naderpoor N, de Courten MPJ, et al. Vitamin D supplementation has no effect on insulin sensitivity or secretion in vitamin D-deficient, overweight or obese adults: a randomized placebo-controlled trial. Am J Clin Nutr. 2017; 105(6):1372–1381.

7. Vimaleswaran KS, Berry DJ, Lu C, et al. Causal relationship between obesity and vitamin D status: Bi-directional Mendelian randomization analysis. PLoS Med. 2013; 10(2):e1001383.

8. Menendez C, Lage M, Peino R, et al. Retinoic acid and vitamin D regulate leptin secretion and receptor expression in rat adipose tissue. Mol Cell Endocrinol.2001; 178(1-2) :25–30.

9. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin–angiotensin system. J Clin Invest. 2002; 110(2):229–238.

10. Forman JP, Giovannucci E, Holmes MD, et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension. 2007; 49(5):1063–1069.

11. Beveridge LA, Struthers AD, Khan F, et al. Effect of vitamin D supplementation on blood pressure: a systematic review and meta-analysis. J Hypertens. 2015; 33(5):913 –926.

12. Pilz S, Verheyen N, Grübler MR, Tomaschitz A, März W. Vitamin D and cardiovascular disease prevention. Nat Rev Cardiol. 2016; 13(7):404–417.

13. Wu-Wong JR, Nakane M, Ma J, et al. Effects of vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis. 2006; 186(1):20–28.

14. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008; 117(4):503–511.

15. Talmor Y, Golan E, Benchetrit S, et al. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol. 2008; 294:F1059–F1064.

16. Zittermann A, Schleithoff SS, Tenderich G, et al. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003; 41(1):105–112.

17. Pilz S, März W, Wellnitz B, et al. Association of vitamin D deficiency with heart failure and sudden cardiac death. Eur Heart J. 2008; 29(2):225–232.

18. Witham MD, Crighton LJ, Gillespie ND, et al. The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial. Circ Heart Fail. 2010; 3(2):195–201.

19. Manson JE, Cook NR, Lee IM, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019; 380:33–44.

20. Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev. 2014; CD007470.

21. Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press; 2011.

22. Palacios C, Gonzalez L. Is vitamin D deficiency a major global public health problem? J Steroid Biochem Mol Biol. 2014;144 Pt A:138–145.

23. Mithal A, Wahl DA, Bonjour JP, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009; 20(11):1807–1820.

24. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004; 338(2):143–156.

25. Scragg R, Stewart AW, Waayer D, et al. Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the Vitamin D Assessment Study: a randomized clinical trial. JAMA Cardiol. 2017; 2(6):608–616.

26. Grant WB, Lahore H, McDonnell SL, et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients. 2020; 12(4):988.

27. Anderson JL, May HT, Horne BD, et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol. 2010; 106(7): 963 –968

Prof. Dr. Md. Ehsanul Islam
MBBS, M.Phil
Professor of Biochemistry,
Ad-din Akij Medical College, Khulna.
email: ehsan.somcbc@gmail.com

Received: 29 Sep 2024
Accepted: 17 Oct 2024